{
    "Trade/Device Name(s)": [
        "VIDAS\u00ae CEA (S) Assay"
    ],
    "Submitter Information": "bioM\u00e9rieux, Inc.",
    "510(k) Number": "K080194",
    "Predicate Device Reference 510(k) Number(s)": [
        "K023893",
        "K023894"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DHX"
    ],
    "Summary Letter Date": "September 29, 2008",
    "Summary Letter Received Date": "September 30, 2008",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 866.6010"
    ],
    "Regulation Name(s)": [
        "Tumor associated antigen immunological test systems"
    ],
    "Analyte Class(es)": [
        "immunology",
        "cancer molecular"
    ],
    "Analyte(s)": [
        "Carcinoembryonic antigen"
    ],
    "Specimen Type(s)": [
        "Serum"
    ],
    "Specimen Container(s)": [
        ""
    ],
    "Instrument(s)/Platform(s)": [
        "VIDAS instruments"
    ],
    "Method(s)/Technology(ies)": [
        "Enzyme Linked Fluorescent Assay (ELFA)"
    ],
    "Methodologies": [
        "Immunoassay sandwich",
        "Enzyme-linked fluorescence detection"
    ],
    "Submission Type(s)": [
        "Assay",
        "System"
    ],
    "Document Summary": "FDA 510(k) summary for VIDAS\u00ae CEA (S) Assay for quantitative measurement of carcinoembryonic antigen in human serum using ELFA on VIDAS instruments",
    "Indications for Use Summary": "Automated quantitative test for carcinoembryonic antigen measurement in serum on VIDAS instruments, indicated as an aid in monitoring cancer patients with changing CEA concentrations",
    "fda_folder": "Immunology"
}